Add to ORKGSorafenib in the management of metastatic renal cell carcinoma C. Guevremont bSc, C. Jeldres md, P. Perrotte md, and P.I. Karakiewicz m
The discovery of a relationship for the VHL tumor suppressor gene, hypoxia inducible factor-1 alpha,...
目的 探讨索拉非尼治疗转移性肾癌的疗效及预后预测因素. 方法 经病理确诊的转移性肾癌患者51例.口服索拉非尼治疗,同期联合或不联合干扰素、全身化疗,治疗2周期进行疗效评价,观察客观疗效.将其与临床特征...
Metastatic renal cell carcinoma (RCC) was, until recently, considered a challenging disease to treat...
Ding-Wei Ye, Hai-Liang Zhang 1Department of Urology, Fudan University Shanghai Cancer Center, 2Depar...
Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted t...
Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to u...
Background: Collecting duct carcinoma (CDC) is a rare and aggressive variant of renal cell carcinoma...
In hepatocellular carcinoma, sorafenib is the only active medical treatment validated to date. Soraf...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma
Objective To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell ca...
The molecular-targeted agent sorafenib is the first anticancer agent able to slow the progression of...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Renal cell carcinoma (RCC) represents five percent of adult epithelial cancers and clear cell RCC is...
<p>The performed study compared the toxic effects caused by the administration of sorafenib with the...
The discovery of a relationship for the VHL tumor suppressor gene, hypoxia inducible factor-1 alpha,...
目的 探讨索拉非尼治疗转移性肾癌的疗效及预后预测因素. 方法 经病理确诊的转移性肾癌患者51例.口服索拉非尼治疗,同期联合或不联合干扰素、全身化疗,治疗2周期进行疗效评价,观察客观疗效.将其与临床特征...
Metastatic renal cell carcinoma (RCC) was, until recently, considered a challenging disease to treat...
Ding-Wei Ye, Hai-Liang Zhang 1Department of Urology, Fudan University Shanghai Cancer Center, 2Depar...
Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted t...
Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to u...
Background: Collecting duct carcinoma (CDC) is a rare and aggressive variant of renal cell carcinoma...
In hepatocellular carcinoma, sorafenib is the only active medical treatment validated to date. Soraf...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma
Objective To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell ca...
The molecular-targeted agent sorafenib is the first anticancer agent able to slow the progression of...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Renal cell carcinoma (RCC) represents five percent of adult epithelial cancers and clear cell RCC is...
<p>The performed study compared the toxic effects caused by the administration of sorafenib with the...
The discovery of a relationship for the VHL tumor suppressor gene, hypoxia inducible factor-1 alpha,...
目的 探讨索拉非尼治疗转移性肾癌的疗效及预后预测因素. 方法 经病理确诊的转移性肾癌患者51例.口服索拉非尼治疗,同期联合或不联合干扰素、全身化疗,治疗2周期进行疗效评价,观察客观疗效.将其与临床特征...
Metastatic renal cell carcinoma (RCC) was, until recently, considered a challenging disease to treat...